Fig. 2

Genomic landscape of 59 patients with melanoma. NRAS mutation and CDKN2A deletion were the most commonly detected mutations, with no statistically significant difference between responder and non-responder groups. Neither BRAF^V600 nor KIT mutational status affected treatment outcome of immunotherapy